Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
作者信息
Halpern Anna B, Othus Megan, Huebner Emily M, Scott Bart L, Hendrie Paul C, Percival Mary-Elizabeth M, Becker Pamela S, Smith Heather A, Oehler Vivian G, Orozco Johnnie J, Cassaday Ryan D, Gardner Kelda M, Chen Tara L, Buckley Sarah A, Orlowski Kaysey F, Anwar Asma, Estey Elihu H, Walter Roland B
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Department of Medicine, Division of Hematology, University of Washington.
出版信息
Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.
Abstract
摘要
相似文献
1
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.针对复发/难治性急性髓系白血病及其他高级别髓系肿瘤，进行克拉屈滨、大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子联合剂量递增米托蒽醌的I/II期试验。
Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.
2
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).一项关于克拉屈滨（2-氯脱氧腺苷）、阿糖胞苷和粒细胞集落刺激因子联合用于难治性急性髓系白血病诱导治疗的多中心、开放、非对照、II期研究——波兰成人白血病组（PALG）报告
Eur J Haematol. 2003 Sep;71(3):155-62. doi: 10.1034/j.1600-0609.2003.00122.x.
3
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.FLAGM（氟达拉滨+大剂量阿糖胞苷+粒细胞集落刺激因子+米托蒽醌）治疗复发或难治性急性髓系白血病的II期研究
Int J Hematol. 2019 Apr;109(4):418-425. doi: 10.1007/s12185-019-02606-0. Epub 2019 Feb 6.
4
Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.用克拉屈滨、阿糖胞苷、米托蒽醌和粒细胞集落刺激因子治疗高危急性髓系白血病，随后过渡到清髓性异基因造血干细胞移植：病例系列
Transplant Proc. 2018 Jan-Feb;50(1):246-249. doi: 10.1016/j.transproceed.2017.11.019.
5
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.CLAG-M 强化化疗与 7+3 方案治疗 AML 和其他高级别髓系肿瘤后的感染并发症。
Leukemia. 2023 Feb;37(2):298-307. doi: 10.1038/s41375-022-01786-9. Epub 2022 Dec 12.
6
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.克拉屈滨联合大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子（CLAG-M）是一种治疗预后不良的难治性和复发性急性髓系白血病患者的高效挽救方案：波兰成人白血病组的最终报告
Eur J Haematol. 2008 Feb;80(2):115-26. doi: 10.1111/j.1600-0609.2007.00988.x. Epub 2007 Dec 11.
7
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.常用挽救性化疗方案对难治性或复发性急性髓系白血病患者的疗效：一项回顾性队列研究。
Medicine (Baltimore). 2018 Sep;97(39):e12102. doi: 10.1097/MD.0000000000012102.
8
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.线粒体靶向荧光素酶作为复发难治性急性髓系白血病的挽救疗法。
Onkologie. 2001 Aug;24(4):356-60. doi: 10.1159/000055107.
9
Cladribine in the treatment of acute myeloid leukemia.克拉屈滨治疗急性髓系白血病
Leuk Res. 2014 Apr;38(4):425-7. doi: 10.1016/j.leukres.2014.01.005. Epub 2014 Jan 14.
10
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.在复发/难治性急性髓系白血病或其他高级别髓系肿瘤成人患者中，地西他滨进行表观遗传预处理后使用米托蒽醌、依托泊苷和阿糖胞苷：一项1/2期研究
Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.
引用本文的文献
1
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.接受强化化疗的急性髓系白血病患者因毒性而停药。
Blood Neoplasia. 2025 Jun 14;2(3):100129. doi: 10.1016/j.bneo.2025.100129. eCollection 2025 Aug.
2
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.维奈克拉联合克拉屈滨、阿糖胞苷、粒细胞集落刺激因子和米托蒽醌治疗急性髓系白血病和高级别髓系肿瘤的1期试验
Blood Neoplasia. 2025 Mar 3;2(3):100085. doi: 10.1016/j.bneo.2025.100085. eCollection 2025 Aug.
3
Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia.含盐酸米托蒽醌脂质体方案治疗难治性/复发性急性髓系白血病的疗效与安全性
Discov Oncol. 2025 May 12;16(1):727. doi: 10.1007/s12672-025-02526-y.
4
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.lintuzumab-Ac225联合CLAG-M挽救疗法用于复发/难治性急性髓系白血病的1期研究
Leukemia. 2025 Apr;39(4):837-843. doi: 10.1038/s41375-025-02528-3. Epub 2025 Feb 15.
5
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.识别急性髓系白血病成人患者低风险发热性中性粒细胞减少症入院的预测因素。
Blood Adv. 2024 Dec 24;8(24):6161-6170. doi: 10.1182/bloodadvances.2024014291.
6
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.强化再诱导化疗后早期异基因造血细胞移植治疗复发/难治性高级别髓系肿瘤。
Transplant Cell Ther. 2024 Jul;30(7):727.e1-727.e8. doi: 10.1016/j.jtct.2024.05.002. Epub 2024 May 5.
7
Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?维奈托克联合强化化疗：难治性和/或复发性急性髓系白血病的新希望？
J Clin Med. 2024 Jan 18;13(2):549. doi: 10.3390/jcm13020549.
8
Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial.硼替佐米联合高三尖杉酯碱及阿糖胞苷化疗方案治疗难治性或复发性急性髓系白血病的疗效：一项多中心前瞻性II期临床试验
Front Oncol. 2023 Aug 18;13:1142449. doi: 10.3389/fonc.2023.1142449. eCollection 2023.
9
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.初治 AML 患者中索拉非尼联合克拉屈滨、高剂量阿糖胞苷、G-CSF 和米托蒽醌的 1/2 期研究。
Blood Adv. 2023 Sep 12;7(17):4950-4961. doi: 10.1182/bloodadvances.2023010392.
10
Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.CLAG 联合多柔比星脂质体治疗难治或复发急性髓系白血病的疗效和毒性。
Cancer Med. 2023 Jun;12(11):12377-12387. doi: 10.1002/cam4.5938. Epub 2023 May 10.
本文引用的文献
1
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.GCLAM 联合剂量递增米托蒽醌治疗初诊 AML 或其他高级别髓系肿瘤的 1/2 期临床试验。
Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.
2
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.在复发/难治性急性髓系白血病或其他高级别髓系肿瘤成人患者中，地西他滨进行表观遗传预处理后使用米托蒽醌、依托泊苷和阿糖胞苷：一项1/2期研究
Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.
3
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.复发或难治性急性髓系白血病成人患者早期死亡的预测
Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11.
4
How I treat refractory and early relapsed acute myeloid leukemia.我如何治疗难治性和早期复发的急性髓系白血病。
Blood. 2015 Jul 16;126(3):319-27. doi: 10.1182/blood-2014-10-551911. Epub 2015 Apr 7.
5
Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.环孢素联合普伐他汀、米托蒽醌和依托泊苷对复发/难治性成人急性髓系白血病多药耐药的调节作用：一项1/2期研究
Leuk Lymphoma. 2013 Nov;54(11):2534-6. doi: 10.3109/10428194.2013.777836. Epub 2013 Mar 27.
6
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.回顾性比较克拉屈滨与氟达拉滨联合高剂量阿糖胞苷联合或不联合粒细胞集落刺激因子作为急性髓细胞白血病的挽救疗法。
Haematologica. 2013 Jan;98(1):114-8. doi: 10.3324/haematol.2012.063438. Epub 2012 Jul 16.
7
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.新诊断的急性髓系白血病诱导治疗后早期死亡的预测：一种新的治疗分配范式。
J Clin Oncol. 2011 Nov 20;29(33):4417-23. doi: 10.1200/JCO.2011.35.7525. Epub 2011 Oct 3.
8
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.用高剂量阿糖胞苷和粒细胞集落刺激因子（G-CSF）预处理治疗复发和难治性急性髓系白血病的克拉屈滨。
Br J Haematol. 2011 Oct;155(2):182-9. doi: 10.1111/j.1365-2141.2011.08831.x. Epub 2011 Aug 18.
9
Anthracycline dose intensification in acute myeloid leukemia.急性髓系白血病中蒽环类药物剂量强化
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.
10
High-dose daunorubicin in older patients with acute myeloid leukemia.老年急性髓系白血病患者使用大剂量柔红霉素治疗
N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409.
Zotero 插件